Aurora Spine Corporation (TSXV: ASG | OTCQB: ASAPF), operating through its wholly owned subsidiary, Aurora Spine, Inc., engages in the development and distribution of minimally invasive and interspinous fusion systems. Incorporated in 2013, the company maintains its registered head office in Toronto, Canada, alongside its principal operational facilities in Carlsbad, California.
An extensive product catalog features advanced screwless and minimally invasive solutions tailored for patients suffering from degenerative disc diseases, including the ZIP process lumbar line and the SiLO sacroiliac joint system. Driven by its proprietary DEXA Technology platform, which features the market’s first bone density-matched spinal implants, Aurora Spine combines elegant, intuitive engineering with patient-centric technology to simplify complex spinal procedures, improve operating room efficiencies, and protect natural anatomical profiles.
Comprehensive Healthcare Systems Inc. (TSXV: CHS | OTCQB: CMHSF) functions as an Alberta-incorporated enterprise serving as the corporate parent of its Delaware-based operating subsidiary. Supervised by healthcare technology specialists, the organization delivers vertically integrated Software-as-a-Service solutions engineered to digitize outmoded medical administrative infrastructures. By implementing highly reliable, automated transaction engines, the corporation helps institutional clients migrate complex benefits operations away from legacy frameworks into secure, modern workflows.
The technological core of the enterprise relies on its state-of-the-art Novus 360 Healthcare Welfare and Benefits Administration platform. This comprehensive SaaS product equips self-funded employers, labor unions, and medical providers with the necessary digital tools to manage day-to-day claims, records, and compliance tasks. From its operational headquarters, the group combines specialized technology-enabled services with proprietary pricing transparency modules to scale its North American footprint, giving retail investors and enterprise partners direct exposure to high-volume healthcare logistics.
Bedrocan Canada operates as a premier pharmaceutical grade medical cannabis enterprise solely dedicated to serving clinical research initiatives and healthcare patients. Originally brought to the public markets through a strategic reverse takeover backed by financial venture networks, the company established itself as a foundational leader in Canada’s federally regulated medicinal cannabis framework. By utilizing strict pharmaceutical cultivation methodologies, the corporation ensures that its standardized botanical varieties maintain a completely uniform composition of active cannabinoids across every single production cycle.
Initial corporate capitalization and rapid operational expansion were heavily accelerated by the PowerOne Group, which served as the sole agent, equity sponsor, and lead financial advisor across multi-million dollar private placements and public listings. Following these high profile capital market engagements, which earned top industry transaction awards from the Private Capital Markets Association, the entity completed a major merger with Tweed Marijuana Inc. to help form Canopy Growth Corp., creating the nation’s largest public medicinal cannabis organization at the time. Today, Bedrocan continues to leverage its extensive history of government regulated supply across global jurisdictions to deliver highly reliable, science based therapeutic options to patients and prescribing physicians worldwide.
Blueberries Medical Corp. (CSE: BBM | OTCQB: BBRRF) operates as a premier Latin American licensed producer focused on the cultivation, processing, and distribution of naturally grown, premium quality cannabis. Guided by a multidisciplinary leadership team with deep background in industrial agriculture, plant genetics, specialized extraction, medicine, and international pharmacology, the enterprise is fully authorized to navigate the global medical marketplace. The company holds comprehensive regulatory permits required for the commercial cultivation, domestic distribution, and international export of both CBD and THC-based medical cannabis solutions.
Agricultural and manufacturing operations are ideally situated within the fertile Bogotá Savanna of central Colombia, while simultaneously establishing a strategic operational presence in Argentina. By combining the unique geographic and cost advantages of these regions with advanced scientific testing and standardized extraction protocols, Blueberries is uniquely positioned to become a leading international supplier of medicinal-grade cannabis oil extracts. This balanced commercial model allows the business to deliver reliable, highly consistent therapeutic raw materials to pharmaceutical networks and healthcare partners across multiple global markets.
SLANG Worldwide Inc. was a prominent cannabis consumer packaged goods company that specialized in the ownership, licensing, and marketing of regional cannabis brands across the United States. Founded in 2017 and formerly traded under the ticker symbol SLNG on the Canadian Securities Exchange, the Toronto-based entity scaled a diverse portfolio that served the flower, concentrates, edibles, and beverage categories. The firm operated an asset-light brand-licensing model designed to rapidly deploy market-proven formulations into highly regulated state economies.
Liquidation proceedings defined the company’s final corporate structure following a prolonged liquidity crunch and an inability to restructure its secured debt obligations. In late 2024, SLANG Worldwide finalized a lender-approved wind-down plan, resulting in a formal assignment into bankruptcy under Canada’s Bankruptcy and Insolvency Act alongside a court-appointed receivership of its core United States operating assets. All member directors resigned and common shares were permanently delisted from public brokerages, concluding the company’s active role as a commercial distributor in the modern legal cannabis sector.
Merus Labs International Inc. was a specialty pharmaceutical company focused on the acquisition, optimization, and licensing of established legacy and growth medicines. Headquartered in Toronto, Canada, the company built a scalable commercial platform that served critical treatment categories across Europe, North America, and selected global markets. The firm specialized in acquiring stable, market-proven product lines from tier-one manufacturers and introducing targeted re-launch marketing programs to maximize patient access and brand equity.
Corporate operations as a standalone issuer concluded following a definitive plan of arrangement that resulted in the company’s acquisition by Amsterdam-based Norgine B.V. This transaction integrated Merus’s diverse portfolio of core products, including specialized treatments for coronary artery disease, thromboembolism, and gastrointestinal infections, directly into Norgine’s extensive European distribution infrastructure. Following the successful closure of the deal, the company was transitioned into a private subsidiary, and its common shares were permanently delisted from the Toronto Stock Exchange and NASDAQ public brokerages.
Aleafia Health brings Canadians medical cannabis care through nationwide clinics, world-class cultivation and distribution facilities, and innovative research. Experiential knowledge of medical cannabis therapy, a rapidly evolving science, helps ensure physicians make recommendations that have been proven effective through historical data, helping to avoid treatments based on trial and error. The company’s staff of trained educators provide learning sessions for new patients, providing ongoing consultation ensuring patients are matched with the most appropriate treatment.
Alegro Health Corp. (TSX-V: AGO), a provider of medical, surgical and rehabilitation and disability management services.
Antisense Therapeutics is a biopharmaceutical drug discovery and development company whose mission is to create, develop and commercialize novel antisense therapeutics for a variety of drug candidates including Duchenne Muscular Dystrophy (DMD), Multiple Sclerosis (MS), and Acromegaly.
Beckley Psytech Ltd is a private biopharmaceutical company dedicated to improving the lives of people living with neuropsychiatric disorders by developing rapid-acting psychedelic medicines. Founded in 2019, and underpinned by more than two decades of pioneering scientific research from the Beckley Foundation, Beckley Psytech combines world-leading psychedelic science with extensive drug development expertise in order to optimise patient outcomes, improve treatment opportunities and ease the burden neuropsychiatric conditions have on individuals, healthcare systems and society.
Canabo wholly owns and operates Cannabinoid Medical Clinics, or CMClinics, Canada’s largest physician led referral-only clinics for medical cannabis. Established in 2014, Canabo now has 22 clinics across Canada, with additional locations planned to open in 2018. Canabo operates referral-only medical clinics dedicated to evaluating the suitability of prescribing, and monitoring cannabinoid treatments for patients suffering from chronic pain and disabling illnesses. Clinics operated by Canabo are staffed by physicians and qualified health care practitioners specifically trained to assess patient suitability for cannabinoid treatment, recommend treatment regimes, and monitor treatment progress.
Canopy Growth advances the world’s perception of cannabis by focusing on research, product development and innovative production capabilities – all presented through brands people trust.
ChondroGene Limited is focussed on the application of functional genomics to enable early diagnosis and personalized therapeutic intervention based on disease-specific biomarkers. The Company has developed a novel approach, the Sentinel Principle(TM), to detect and stage virtually any disease or medical condition from a simple blood sample. GeneNews is currently applying the Sentinel Principle in major areas with unmet clinical needs such as cancer, arthritis, cardiovascular disease and neurological disorders. GeneNews’ first product in development, ColonSentry(TM), is a blood-based test that can detect colon cancer and pre-cancerous polyps.
Defence Therapeutics is a publicly-traded clinical-stage biotechnology company developing and engineering the next generation of radio-immuno-conjugate and ADC products using its proprietary platform in addition to novel immune-oncology vaccines. The core of Defence Therapeutics platform is the ACCUM® technology, which enables precision delivery of radio-immuno-conjugates or ADCs in their intact form to target cells, and vaccine antigens. As a result, increased efficacy and potency can be reached against catastrophic illness such as cancer and infectious diseases.
Diagnos is a leader in artificial intelligence and healthcare technical services including algorithm development, data analysis, and image processing ever since 2001. DIAGNOS Inc. of Canada provides software solutions. The Company develops and publishes a knowledge extraction platform that allows for the enhancement and intelligent analysis of digital retinal images. DIAGNOS serves healthcare industry worldwide.
Elite Imaging, Inc. provides medical imaging and radiology services. The Company offers magnetic resonance imaging (MRI), healthcare screening, breast implants, digital mammography, x-ray, nuclear medicine, and echocardiography services. Elite Imaging serves customers in the United States.
Lorus Therapeutics Inc. (TSX: LOR) (the “Company”), a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer.
MediPharm Labs, a contract and development and manufacturing company, brings a pharmaceutical perspective to the cannabis industry; working to internationally recognized pharma-quality standards, our cannabis products that are PURE, TRUSTED and PRECISELY DOSABLE for patients and end consumers. MediPharm Labs Corp., together with its subsidiaries, produces and sells pharmaceutical-grade cannabis oil and concentrates for derivative products in Canada and Australia. It also provides cannabis contract processing services to licensed producers and growers; and tolling services to licensed cultivators in Canada. In addition, the company supplies purified cannabis concentrate raw materials and product formulations for ready-to-sell advanced cannabis products. Further, it engages in the real estate business. The company was founded in 2015 and is headquartered in Barrie, Canada.
Sante Veritas Therapeutics Inc. (CSE: SV) is striving to be one of Canada’s premier producer of pharma-grade, innovative, market-informed, cannabis products developed through state of the art genetics and grow environments, balancing market responsiveness with efficient production capabilities. PowerOne was finder and early investor in the company’s $7.7M financing in February 2017 and Co-Agent in the company’s $16M financing in December 2017. Sante Veritas has also announced a merger with Baker Technologies Inc., Briteside Holdings LLC, and Sea Hunter to form Tilt Holdings Inc., expanding into the United States and forming one of the most comprehensive industry platforms.
TILT Holdings Inc. (“TILT” or the “Company”), which is a vertically-integrated technology and infrastructure platform delivering a comprehensive range of products and services across the cannabis industry.
True Health, also known as Sante Veritas Therapeutics, applied to the federal government and began the process to become a licensed producer for its marijuana for medical purposes regulations program.
Canopy Growth Corporation, formerly Tweed Marijuana Inc., is a cannabis company based in Smiths Falls, Ontario. Tweed was founded by Bruce Linton and Chuck Rifici in 2013, and renamed Canopy Growth Corporation in 2015 after a merger with Bedrocan Canada.
Xanthic, through its wholly-owned operating subsidiary, Xanthic Biopharma Limited, provides valuable intellectual property to cannabis industry participants, enabling its strategic partners to produce high quality, innovative, non-combustible cannabis, and cannabis-infused products which deliver consistent THC and/or CBD levels and improved bioavailability. Using a patent-pending proprietary process, Xanthic allows its strategic partners to deliver superior cannabinoid solubility, improved bioavailability, accurate micro-dosing and greater consistency versus competitive infused products. Through its investment in Xanthic Beverages, Xanthic has access to non-cannabis derived CBD-infused products that qualify for distribution outside of the cannabis dispensary network and into mainstream retail. www.xanthicbio.com
